The AKT1 Knockout CAL-27 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal population of CAL-27 cells with targeted disruption of the AKT1 gene. This heterogeneous knockout pool, derived without single-cell cloning, provides a physiologically relevant loss-of-function model for investigating AKT1 signaling in the context of oral squamous cell carcinoma. The polyclonal format minimizes clonal artifacts and captures the diversity of genomic editing outcomes, enabling robust analysis of AKT1-dependent phenotypes.
The CAL-27 cell line was established from a tongue squamous cell carcinoma resected from a male patient. It is a widely used model of oral carcinogenesis, exhibiting classical epithelial morphology, anchorage-independent growth, and robust tumorigenic potential. These cells harbor multiple genetic alterations, including overexpression of EGFR and constitutive activation of the PI3K/AKT/mTOR pathway, making them particularly relevant for dissecting oncogenic signaling and evaluating targeted therapies.
AKT1 encodes a serine/threonine kinase that functions as a central node in multiple pro-survival and growth-promoting cascades. Upon growth factor stimulation, receptor tyrosine kinases such as EGFR, IGFR, and HER2 activate PI3K, generating PIP3 that recruits AKT1 and PDK1 to the membrane. PTEN antagonizes this process by dephosphorylating PIP3. Activation via phosphorylation at Thr308 and Ser473 enables AKT1 to phosphorylate downstream effectors: it inhibits GSK3??, FOXO1/3a, and BAD to block apoptosis; phosphorylates TSC2 to relieve mTORC1 inhibition, enhancing protein synthesis through RPS6KB1 and EIF4EBP1; and modulates cell cycle via MDM2, p21Cip1, and p27Kip1. AKT1 interacts with scaffolding protein APPL1 and is regulated by mTORC2/RICTOR and phosphatases like PP2A.
In CAL-27 oral cancer cells, which exhibit high basal AKT activity, CRISPR-mediated disruption of AKT1 profoundly attenuates oncogenic signaling. Loss of AKT1 function leads to decreased phosphorylation of downstream targets, including GSK3?? and FOXO proteins, while promoting pro-apoptotic activity and impairing mTORC1-driven anabolic pathways. This knockout phenotype reflects the dependency of oral squamous cell carcinoma on AKT1-mediated survival signals, resulting in reduced proliferation, increased apoptosis, and diminished invasive capacity. The polyclonal nature of the edited population allows study of these phenotypes across varying knockout efficiencies, mirroring tumor heterogeneity.
Researchers can employ the AKT1 Knockout CAL-27 Polyclonal Cells in diverse experimental paradigms, including signaling dissection via western blotting and phospho-kinase arrays, proliferation and viability assays (MTS/MTT, colony formation), apoptosis detection (Annexin V/PI flow cytometry), and migration/invasion studies (wound healing, Matrigel). The model is also ideal for PI3K pathway inhibitor screening and transcriptomic profiling by RNA-seq to identify AKT1-dependent gene expression changes. For further information or ordering, please contact Ascent Research.
